ClinicalTrials.gg
RecruitingNCT07635940Updated Oct 8, 2026

Effects of Transcranial Magnetic Stimulation on Social Cognition, Cognitive Processing, and Functional Brain Architecture

An interventional study of continuous theta burst stimulation (cTBS) and Intermittent theta burst stimulation (iTBS) in Psychopathy, sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 8, 2026Now RecruitingStudy contact changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Antisocial Personality Disorder with a site in United States — 4 open to participants now, 6 under way, none of them phase 3. Antisocial Personality Disorder · United States.

Planned enrollment
14th of 18
60 · median 188
Started
2026
the only one that year
No phase
13 of 26
4 open now
Registered
26th of 26
by date
Lead sponsor
2 of 26
University of Colorado, Denver

Among the 26 studies in Antisocial Personality Disorder with a site in United States, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, and was the 26th registered.

Antisocial Personality Disorder

67 studies on the registry are indexed under Antisocial Personality Disorder; 10 are open to participants now.

Browse Antisocial Personality Disorder studies →

Open to participants now

4 of the 26 studies in Antisocial Personality Disorder with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Antisocial Personality Disorder studies recruiting now, none set no upper age limit and 8 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Antisocial Personality Disorder with a site in United States, or all of them as a file.
02

Study summary

This clinical trial will examine whether transcranial magnetic stimulation (TMS), a noninvasive form of brain stimulation, can influence social cognition, cognitive processing, and brain function in adults with elevated psychopathic traits. The study will also evaluate the safety and feasibility of delivering TMS in this population.

Participants will be randomly assigned to receive either active TMS or sham (placebo-like) TMS. The study will compare outcomes between participants receiving active versus sham TMS and will evaluate changes from before to after TMS exposure.

Participants will:

  • Complete a baseline magnetic resonance imaging (MRI) brain scan.
  • Receive three single-session TMS interventions.
  • Complete a post-intervention MRI brain scan.
  • Complete assessments of social cognition.
  • Complete assessments of cognitive processing.

The primary objectives are to determine whether TMS can influence social cognition, cognitive processing, and functional brain organization and connectivity in adults with elevated psychopathic traits.

Read the detailed description

Psychopathic traits are associated with impairments in social cognition, cognitive processing, and alterations in functional brain network organization. Neuroimaging studies have implicated abnormalities in brain regions involved in cognitive control and social information processing, including the right dorsolateral prefrontal cortex (dlPFC) and right temporoparietal junction (TPJ). Transcranial magnetic stimulation (TMS) is a noninvasive neuromodulation technique capable of altering neural activity within targeted brain networks and provides an experimental method for examining the causal contribution of these regions to cognitive and social functioning.

This randomized, sham-controlled clinical trial will evaluate whether theta burst stimulation targeting the right dlPFC or right TPJ influences social cognition, cognitive processing, and functional brain network organization in adults with elevated psychopathic traits. Participants will be randomly assigned to receive inhibitory continuous theta burst stimulation (cTBS) targeting the right dlPFC, excitatory intermittent theta burst stimulation (iTBS) targeting the right TPJ, or sham stimulation. Stimulation targets will be individualized using participant-specific neuroimaging data.

Participants will complete baseline and post-intervention assessments that include functional magnetic resonance imaging (fMRI), measures of social cognition, and measures of cognitive processing. Functional neuroimaging will be used to evaluate changes in brain network organization and connectivity associated with stimulation. Behavioral assessments will evaluate social cognitive processes, including emotion processing and perspective taking, as well as cognitive processes related to attention and cognitive control.

Analyses will compare active stimulation conditions with sham stimulation on measures of social cognition and cognitive processing. Neuroimaging analyses will evaluate both within-subject changes from pre- to post-stimulation and between-group differences in functional brain network organization and connectivity.

The primary objectives are to determine whether theta burst stimulation can influence social cognition, cognitive processing, and functional brain network organization in adults with elevated psychopathic traits and to evaluate the safety and feasibility of delivering TMS in this population. Findings from this study may help clarify the neural mechanisms underlying psychopathic traits and inform future development of targeted neuromodulation interventions.

03

Conditions studied

  • Psychopathy

Keywords

  • Psychopathy
  • Transcranial Magnetic Stimulation
  • Theta Burst Stimulation
  • Neuromodulation
  • Social Cognition
  • Emotion Recognition
  • Theory of Mind
  • Social Decision Making
  • Cognitive Processing
  • Cognitive Control
  • Executive Function
  • Functional Connectivity
  • Resting-State fMRI
  • Dorsolateral Prefrontal Cortex
  • Temporal Parietal Junction
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-60 years.
  • Elevated psychopathy as defined by the self-report psychopathy scale.
  • IQ >= 80.
  • No prior diagnosis or current risk of Autism as defined by the autism spectrum quotient.
  • Negative urine drug screen.
  • At least 7 Days of abstinence from substance use (excluding nicotine)
  • Able to provide .
  • No change in psychiatric medication regimen, or medication-free, for 4 weeks before study.
  • Adequate English proficiency to complete study procedures and assessments.

Exclusion criteria

Exclusion Criteria:

  • Current or lifetime psychotic disorder, schizophrenia, schizoaffective disorder, bipolar disorder, or autism spectrum disorder.
  • IQ \< 80.
  • neurological disorder or medical illness that would make study participation unsafe, including a history of seizures or significant cardiovascular disease.
  • Clinically significant abnormality identified on baseline MRI.
  • to MRI or inability to undergo MRI scanning.
  • Current pregnancy or breastfeeding.
  • History of head injury resulting in loss of consciousness greater than 15 minutes.
  • Diagnosis of dementia.
  • Current prescription for benzodiazepines or anticonvulsants.
  • Metal implants or non-removable metal objects above the waist.
  • Lifetime history of prior clinical treatment with transcranial magnetic stimulation (TMS).
  • Serious risk of suicide or homicide.
  • Unable or unwilling to comply with study procedures.
  • History of intractable migraine.
  • Claustrophobia or inability to tolerate enclosed spaces required for MRI procedures.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    active dlPFC sham TPJ

    Subjects in this group will receive active continuous theta burst stimulation (cTBS) to the individually defined region of the dlPFC and sham to the TPJ.

    Device: continuous theta burst stimulation (cTBS)

  • Active comparator
    active TPJ sham dlPFC

    Subjects in this group will receive active intermittent theta burst stimulation to the individually defined region of the TPJ and sham to the dlPFC.

    Device: Intermittent theta burst stimulation (iTBS)

  • Sham comparator
    sham

    Subjects in this group will receive sham stimulation to the dlPFC and TPJ.

    Device: Sham

Interventions

  • Devicecontinuous theta burst stimulation (cTBS)

    Continuous theta burst stimulation (cTBS) will be delivered using transcranial magnetic stimulation (TMS) targeting the right dorsolateral prefrontal cortex (dlPFC). cTBS is a patterned form of repetitive TMS designed to modulate neural activity within targeted brain networks involved in cognitive control and social cognition. Stimulation targets will be individualized using participant-specific neuroimaging data.

  • DeviceIntermittent theta burst stimulation (iTBS)

    Intermittent theta burst stimulation (iTBS) will be delivered using transcranial magnetic stimulation (TMS) targeting the right temporoparietal junction (TPJ). iTBS is a patterned form of repetitive TMS designed to modulate neural activity within targeted brain networks involved in social cognition and perspective taking. Stimulation targets will be individualized using participant-specific neuroimaging data

  • DeviceSham

    Sham transcranial magnetic stimulation will be delivered using procedures designed to mimic the sensory experience of active stimulation without producing the intended neuromodulatory effects. Stimulation targets and study procedures will mirror those used in the active intervention arms.

06

What researchers measure

Primary outcomes

  1. Social Cognition Task Battery Performance

    Performance on a social cognition task battery assessing facial emotion recognition (Emotion Recognition Task), perspective taking (Visual Perspective Taking Task), theory of mind (Movie Assessment of Social Cognition Task), and social decision-making (Altruistic/Antisocial game). Accuracy and reaction time will be analyzed using mixed-effects models to compare active stimulation versus sham stimulation across tasks. Higher accuracy values indicate better performance, whereas lower reaction times indicate better performance.

    Time frame: within 10 minutes after the intervention.

  2. Serial and Parallel Cognitive Processing Task Performance

    Performance on the Miller serial/parallel cognitive processing task. Trial-level accuracy and/or reaction time will be analyzed using mixed-effects models to compare active stimulation versus sham stimulation across serial and parallel processing conditions.

    Time frame: within 10 minutes after the intervention.

Secondary outcomes

  1. Change in Resting-State Functional Connectivity

    Resting-state functional magnetic resonance imaging will be used to evaluate changes in functional connectivity within stimulation-relevant brain networks from baseline to post-intervention. Analyses will examine frontoparietal network connectivity for right dorsolateral prefrontal cortex stimulation and default mode network connectivity for right temporoparietal junction stimulation, including within-subject change and between-group comparisons of active versus sham stimulation.

    Time frame: From the date of baseline fMRI until the first TMS session, assessed 2 times (baseline and post-TMS) up to 2 months after the baseline session. Post-TMS fMRI scan will be conducted within 30 minutes after the intervention.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Tillem S, Weinstein H, Baskin-Sommers A. Psychopathy is associated with an exaggerated attention bottleneck: EEG and behavioral evidence from a dual-task paradigm. Cogn Affect Behav Neurosci. 2021 Aug;21(4):881-893. doi: 10.3758/s13415-021-00891-z. Epub 2021 Apr 5. PubMed 33821459 ↗
  • Jeurissen D, Sack AT, Roebroeck A, Russ BE, Pascual-Leone A. TMS affects moral judgment, showing the role of DLPFC and TPJ in cognitive and emotional processing. Front Neurosci. 2014 Feb 13;8:18. doi: 10.3389/fnins.2014.00018. eCollection 2014. PubMed 24592204 ↗
  • Saxe R, Kanwisher N. People thinking about thinking people. The role of the temporo-parietal junction in "theory of mind". Neuroimage. 2003 Aug;19(4):1835-42. doi: 10.1016/s1053-8119(03)00230-1. PubMed 12948738 ↗
  • Drayton LA, Santos LR, Baskin-Sommers A. Psychopaths fail to automatically take the perspective of others. Proc Natl Acad Sci U S A. 2018 Mar 27;115(13):3302-3307. doi: 10.1073/pnas.1721903115. Epub 2018 Mar 12. PubMed 29531085 ↗
  • Song Z, Jones A, Corcoran R, Daly N, Abu-Akel A, Gillespie SM. Psychopathic traits and theory of mind task performance: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2023 Aug;151:105231. doi: 10.1016/j.neubiorev.2023.105231. Epub 2023 May 10. PubMed 37172923 ↗

Related links

Individual participant data

Plan to share: Yes — Upon study completion, neuroimaging and behavioral data will be shared via the brain imaging data sharing database OpenNeuro. Metadata for the study will be included, such as the study protocol. All publications from this data by the PI or the PI's lab will first preregister the analysis, and all accepted publications will share the analytic code with a link to the GitHub repository in the publication

Supporting information: Study protocol, Statistical analysis plan, Analytic code

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2030, 47 months after the start.

Of 25 interventional studies with no phase under Antisocial Personality Disorder, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 47 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jul 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 9, 2026
StartActual
Jul 13, 2026was Jun 2026
Primary completionEst.
Jun 2030
CompletionEst.
Aug 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
University of Colorado Anschutz Medical Campus is now Recruiting
Sep 29, 2026
Start date
Jun 2026→Jul 13, 2026 (actual)
Sep 29, 2026
Contact
Study contact's phone or email changed: a•••@ucdenver.edu→a•••@cuanschutz.edu. See the current contact
Oct 8, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Colorado Anschutz Medical Campus · Aurora, United StatesContact a•••@ucdenver.edu→a•••@cuanschutz.edu
Oct 8, 2026
Show all 2 updates
  1. Oct 8, 2026
    Contact Study contact's phone or email changed: a•••@ucdenver.edu→a•••@cuanschutz.edu. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Colorado Anschutz Medical Campus · Aurora, United StatesContact a•••@ucdenver.edu→a•••@cuanschutz.edu
    + 1 other change: verification date
  2. Sep 29, 2026
    Not yet recruiting→Recruiting
    University of Colorado Anschutz Medical Campus is now Recruiting
    Start date Jun 2026→Jul 13, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07635940
Responsible party
Sponsor
First posted
Jun 9, 2026
Start date
Jul 13, 2026
Primary completion
Jun 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Drew E Winters, PhD.
Contact
ascend.lab@cuanschutz.edu
303-724-1000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion